logo-loader
viewAmryt Pharma PLC

Amryt Pharma releases Q-2 financials that show strong revenue growth as company issues guidance

Amryt Pharma (Nasdaq: AMYT) CEO Dr Joe Wiley joined Steve Darling from Proactive with news the company saw a nice increase in revenue as they released their Q-2 numbers. Dr Wiley talked about some of the numbers and what was driving that revenue. Wiley also told Proactive the company has, for the first time, set revenue guidance for 2020.

Quick facts: Amryt Pharma PLC

Price: 209 GBX

AIM:AMYT
Market: AIM
Market Cap: £340.26 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market report: Sterling six week lows and further lockdown woes

The FTSE is higher as we head into early afternoon trade with Sterling still loitering around that six week low and news from drug giant AstraZeneca PLC (LON:AZN) that it is putting its coronavirus vaccine trials on hold after a patient participating got poorly which has triggered...

on 9/9/20

2 min read